ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Sees Significant Decline in Short Interest

ThermoGenesis Holdings, Inc. (NASDAQ:THMOGet Rating) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 447,500 shares, a decrease of 27.2% from the August 15th total of 614,700 shares. Based on an average daily trading volume, of 2,910,000 shares, the days-to-cover ratio is currently 0.2 days.

ThermoGenesis Stock Performance

THMO opened at $0.19 on Friday. The firm has a market cap of $5.95 million, a P/E ratio of -0.26 and a beta of 2.77. The firm has a 50-day moving average of $0.22 and a 200 day moving average of $0.39. ThermoGenesis has a fifty-two week low of $0.09 and a fifty-two week high of $2.30.

ThermoGenesis (NASDAQ:THMOGet Rating) last issued its earnings results on Thursday, August 11th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.22). The business had revenue of $3.03 million for the quarter. ThermoGenesis had a negative return on equity of 220.74% and a negative net margin of 80.10%. Equities research analysts predict that ThermoGenesis will post -0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ThermoGenesis

A hedge fund recently bought a new stake in ThermoGenesis stock. Virtu Financial LLC bought a new position in shares of ThermoGenesis Holdings, Inc. (NASDAQ:THMOGet Rating) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 189,671 shares of the company’s stock, valued at approximately $52,000. Virtu Financial LLC owned 1.48% of ThermoGenesis as of its most recent SEC filing. 2.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reduced their price target on shares of ThermoGenesis from $6.00 to $1.00 and set a “buy” rating for the company in a research report on Friday, August 12th.

About ThermoGenesis

(Get Rating)

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

Featured Stories

Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with's FREE daily email newsletter.